Thus far, NanoPhoria has developed proof of concept evidence demonstrating its nano-in-micro platform can deliver therapeutic peptides to cardiomyocytes. These cardiomyocytes possess many possible targets for other biologics that NanoPhoria could utilise, beyond which it is targeting with NP-MP1.